• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why FreightCar America Shares Are Trading Lower By 8%; Here Are 20 Stocks Moving Premarket

    3/28/23 8:33:41 AM ET
    $AXDX
    $BDRX
    $BRDS
    $CDAK
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AXDX alert in real time by email

    Gainers

    • Biodexa Pharmaceuticals (NASDAQ:BDRX) shares rose 76% to $0.8276 in pre-market trading after gaining 65% on Monday.
    • Codiak BioSciences, Inc. (NASDAQ:CDAK) gained 27% to $0.2419 in pre-market trading. Codiak BioSciences shares dropped around 57% on Monday after the company voluntarily filed for protection under Chapter 11 bankruptcy.
    • Bird Global, Inc. (NASDAQ:BRDS) gained 20.4% to $0.1641 in pre-market trading. Bird, on Monday, announced purchases of shares by management and directors.
    • Accelerate Diagnostics, Inc. (NASDAQ:AXDX) climbed 16% to $0.58 in pre-market trading. Accelerate Diagnostics will host a conference call on March 29, 2023 to review fourth quarter and full year results.
    • PVH Corp. (NYSE:PVH) rose 12.3% to $82.65 in pre-market after the company posted better-than-expected results for its fourth quarter and issued strong FY23 earnings forecast.
    • Lion Group Holding Ltd. (NASDAQ:LGHL) gained 10% to $0.2830 in pre-market trading after gaining around 7% on Monday.
    • Silvergate Capital Corporation (NYSE:SI) shares rose 9.1% to $2.15 in pre-market trading. Silvergate Capital shares gained around 15% on Monday after MacroStrategy reported it voluntarily prepaid its Silvergate Bank loan. MicroStrategy prepaid approximately $161.0 million.
    • View, Inc. (NASDAQ:VIEW) shares rose 9% to $0.58 in pre-market trading.
    • Dermata Therapeutics, Inc. (NASDAQ:DRMA) rose 7.9% to $1.50 in pre-market trading after declining around 10% on Monday. Dermata Therapeutics recently announced closing of $5.0 million public offering.
    • Cidara Therapeutics, Inc. (NASDAQ:CDTX) shares rose 7.9% to $1.09 in pre-market trading. Cidara Therapeutics President and CEO Jeffrey Stein acquired a total 50,000 shares at an average price of $1.04.

    Losers

    • WiSA Technologies, Inc. (NASDAQ:WISA) fell 21.7% to $2.82 in pre-market trading after jumping around 89% on Monday.
    • Virgin Orbit Holdings, Inc. (NASDAQ:VORB) shares dropped 14.2% to $0.46 in pre-market trading. Virgin Orbit is extending its pause in operation to pursue investment, CNBC reported, citing a company-wide mail by CEO Dan Hart.
    • CytomX Therapeutics, Inc. (NASDAQ:CTMX) fell 11.7% to $1.58 in pre-market trading after the company posted results for its fourth quarter.
    • Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) fell 9.8% to $0.92 in pre-market. Citius Pharmaceuticals, last month, posted a Q1 loss of $0.02 per share.
    • Foresight Autonomous Holdings Ltd. (NASDAQ:FRSX) fell 9.2% to $0.4302 in pre-market trading after gaining over 5% on Monday.
    • OncoSec Medical Incorporated (NASDAQ:ONCS) shares fell 8.7% to $2.41 in pre-market trading.
    • FreightCar America, Inc. (NASDAQ:RAIL) fell 7.9% to $2.93 in pre-market trading. FreightCar America posted a wider-than-expected loss for its fourth quarter, but sales topped estimates. The company also said it sees FY23 revenue of $400 million to $430 million.
    • Sidus Space, Inc. (NASDAQ:SIDU) shares fell 7.6% to $0.5082 in pre-market trading. Sidus Space filed for common stock offering on Monday.
    • Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) fell 5.9% to $0.4801 in pre-market trading.
    • Invesco Mortgage Capital Inc. (NYSE:IVR) fell 4.6% to $10.69 in pre-market trading after the company announced a cash dividend of $0.40 per share of common stock for the first quarter and issued an update on estimated results of operations, portfolio, liquidity and book value.

    Now Read This: Investor Fear Eases As Dow Jumps Around 200 Points

    Get the next $AXDX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AXDX
    $BDRX
    $BRDS
    $CDAK

    CompanyDatePrice TargetRatingAnalyst
    PVH Corp.
    $PVH
    3/24/2026$82.00 → $74.00Market Perform
    Telsey Advisory Group
    CytomX Therapeutics Inc.
    $CTMX
    3/16/2026$12.00Neutral → Overweight
    Analyst
    CytomX Therapeutics Inc.
    $CTMX
    1/20/2026$10.00Buy
    Guggenheim
    PVH Corp.
    $PVH
    1/14/2026$85.00Buy
    Jefferies
    PVH Corp.
    $PVH
    12/17/2025$82.00Outperform → Market Perform
    Telsey Advisory Group
    INVESCO MORTGAGE CAPITAL INC
    $IVR
    12/15/2025$9.00Buy
    Compass Point
    PVH Corp.
    $PVH
    12/10/2025Neutral
    Guggenheim
    Cidara Therapeutics Inc.
    $CDTX
    11/17/2025Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $AXDX
    $BDRX
    $BRDS
    $CDAK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Telsey Advisory Group reiterated coverage on PVH with a new price target

    Telsey Advisory Group reiterated coverage of PVH with a rating of Market Perform and set a new price target of $74.00 from $82.00 previously

    3/24/26 7:54:39 AM ET
    $PVH
    Garments and Clothing
    Industrials

    CytomX Therapeutics upgraded by Analyst with a new price target

    Analyst upgraded CytomX Therapeutics from Neutral to Overweight and set a new price target of $12.00

    3/16/26 11:34:14 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on CytomX Therapeutics with a new price target

    Guggenheim initiated coverage of CytomX Therapeutics with a rating of Buy and set a new price target of $10.00

    1/20/26 9:23:09 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AXDX
    $BDRX
    $BRDS
    $CDAK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, Regulatory Affairs Bedoya-Toro Munera Maria E bought $1,270 worth of shares (1,000 units at $1.27), increasing direct ownership by 8,333% to 1,012 units (SEC Form 4)

    4 - Dermata Therapeutics, Inc. (0001853816) (Issuer)

    3/17/26 5:44:21 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Points Jeffrey S. exercised 13,264 shares at a strike of $2.48 and bought $30,000 worth of shares (2,000 units at $15.00), increasing direct ownership by 27% to 70,785 units (SEC Form 4)

    4 - SHOULDER INNOVATIONS, INC. (0001699350) (Issuer)

    3/17/26 5:42:34 PM ET
    $SI
    Medical/Dental Instruments
    Health Care

    Director Buchholz Richard bought $14,840 worth of shares (1,000 units at $14.84), increasing direct ownership by 8% to 13,666 units (SEC Form 4)

    4 - SHOULDER INNOVATIONS, INC. (0001699350) (Issuer)

    3/17/26 5:34:29 PM ET
    $SI
    Medical/Dental Instruments
    Health Care

    $AXDX
    $BDRX
    $BRDS
    $CDAK
    SEC Filings

    View All

    SEC Form 20-F filed by Biodexa Pharmaceuticals plc American Depositary Shs

    20-F - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

    3/27/26 5:09:45 PM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Biodexa Pharmaceuticals plc American Depositary Shs

    6-K - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

    3/27/26 5:00:06 PM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by INVESCO MORTGAGE CAPITAL INC

    SCHEDULE 13G/A - Invesco Mortgage Capital Inc. (0001437071) (Subject)

    3/27/26 9:53:27 AM ET
    $IVR
    Real Estate Investment Trusts
    Real Estate

    $AXDX
    $BDRX
    $BRDS
    $CDAK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Preliminary Results for the Year Ended 31 December 2025

    March 27, 2026 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company" or, together with its subsidiaries, the "Group") Preliminary Results for the Year Ended 31 December 2025 Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, announces its audited preliminary results for the year ended 31 December 2025. For more information, please contact: Biodexa Pharmaceuticals PLC Stephen Stamp, CEO Fiona Sharp, CFOTel: +44 (0)29 2048 0180www.biodexapharma.com About Biodexa The Company's lead development programs include eRapa, under development for Familial Adenoma

    3/27/26 5:00:00 PM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Foresight Announces Fourth Quarter and Full Year 2025 Financial Results

    NESS ZIONA, Israel, March 26, 2026 (GLOBE NEWSWIRE) -- Foresight Autonomous Holdings Ltd., (Nasdaq and TASE: FRSX) ("Foresight" or the "Company"), an innovator in 3D perception systems, today reported financial results for the fourth quarter and full year ended December 31, 2025. "We are excited to kick off 2026 with strong momentum, building directly on the significant achievements and strategic partnerships we secured throughout 2025, including major collaborations with leading global players such as Renault Group, Orange, SoftBank Corp. and Audi AG. We believe that these milestones continue to validate our innovative 3D perception and V2X technologies and position Foresight for accelera

    3/26/26 8:55:00 AM ET
    $FRSX
    Computer Software: Prepackaged Software
    Technology

    Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results

    – Closes Private Placement Financing of Up to $104.5 Million – Secures Orphan Drug Designations for QRX003 for Netherton Syndrome (NS) in the U.S. and Europe  – Advances Proposed Expedited Regulatory Approval Pathways in Japan and Saudi Arabia and Secures Fast Track Designation in the U.S. for QRX003 for NS Subsequent to the End of Q4 – Reports Continued Clinical Progress for QRX003 in Netherton Syndrome Clinical Studies including Data Supporting Longer Term Durable Treatment Effect and Safety Profile – Pediatric NS Study Expanded to 7 Children Now Actively Treated with QRX003, Largest Cohort of This Age Group Ever Studied – Ongoing Clinical Data Continues to Support Development of QR

    3/26/26 8:30:00 AM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    $AXDX
    $BDRX
    $BRDS
    $CDAK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Stone Melissa Ann

    4 - PVH CORP. /DE/ (0000078239) (Issuer)

    3/27/26 1:00:41 PM ET
    $PVH
    Garments and Clothing
    Industrials

    SEC Form 3 filed by new insider Bar-On Oren

    3 - Foresight Autonomous Holdings Ltd. (0001691221) (Issuer)

    3/26/26 7:45:11 AM ET
    $FRSX
    Computer Software: Prepackaged Software
    Technology

    SEC Form 3 filed by new insider Himmel Annat

    3 - Foresight Autonomous Holdings Ltd. (0001691221) (Issuer)

    3/26/26 7:45:09 AM ET
    $FRSX
    Computer Software: Prepackaged Software
    Technology

    $AXDX
    $BDRX
    $BRDS
    $CDAK
    Leadership Updates

    Live Leadership Updates

    View All

    Preliminary Results for the Year Ended 31 December 2025

    March 27, 2026 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company" or, together with its subsidiaries, the "Group") Preliminary Results for the Year Ended 31 December 2025 Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, announces its audited preliminary results for the year ended 31 December 2025. For more information, please contact: Biodexa Pharmaceuticals PLC Stephen Stamp, CEO Fiona Sharp, CFOTel: +44 (0)29 2048 0180www.biodexapharma.com About Biodexa The Company's lead development programs include eRapa, under development for Familial Adenoma

    3/27/26 5:00:00 PM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Invesco Mortgage Capital Appoints Veteran Fixed Income and Business Development Strategist Stephanie J. Larosiliere to Board of Directors to Strengthen Stockholder Engagement and Alignment

    ATLANTA, March 10, 2026 /PRNewswire/ -- Invesco Mortgage Capital Inc. (the "Company") (NYSE:IVR) is pleased to announce that Stephanie J. Larosiliere, a veteran fixed income expert with more than two decades of industry experience, has joined its Board of Directors as an executive director, effective March 6, 2026. As Head of Business Strategy and Development for Invesco Ltd. Fixed Income in North America & APAC, Ms. Larosiliere leads a team of client portfolio professionals responsible for strategic business development, including the strategic commercialization of fixed-income

    3/10/26 4:15:00 PM ET
    $IVR
    Real Estate Investment Trusts
    Real Estate

    Shoulder Innovations Appoints MedTech Veteran Drew Hykes to Board of Directors

    GRAND RAPIDS, Mich., March 2, 2026 /PRNewswire/ -- Shoulder Innovations, Inc. ("Shoulder Innovations") (NYSE:SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced the appointment of Drew Hykes to the company's Board of Directors ("Board") and as a member of the Compensation Committee, effective February 26, 2026. Concurrent with Mr. Hykes's appointment, Geoff Pardo will resign as an Independent Director from the Board.   "Drew is a proven healthcare leader, and we are thrilled to welcome him to S

    3/2/26 7:00:00 AM ET
    $SI
    Medical/Dental Instruments
    Health Care

    $AXDX
    $BDRX
    $BRDS
    $CDAK
    Financials

    Live finance-specific insights

    View All

    Sidus Space to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on March 31 at 5:00 PM ET

    CAPE CANAVERAL, Fla., March 24, 2026 /PRNewswire/ -- Sidus Space, Inc.  (NASDAQ:SIDU) (the "Company" or "Sidus"), an innovative space and technology company, today announced that it will host its fourth quarter 2025 financial results conference call at 5:00 PM Eastern Time on Tuesday, March 31, 2026. Event: Sidus Space Fourth Quarter and Full Year 2025 Financial Results Conference CallDate: Tuesday, March 31, 2026Time: 5:00 PM  Eastern TimeLive Call: 1-866-652-5200 (Toll Free); 1-412-317-6060 (International)Webcast: https://app.webinar.net/bKQorD7yJqDFor interested individuals u

    3/24/26 4:46:00 PM ET
    $SIDU
    Telecommunications Equipment
    Telecommunications

    PVH Corp. to Host Conference Call to Discuss Fourth Quarter and Year-End 2025 Earnings Results

    PVH Corp. (NYSE:PVH) today announced that it will release its fourth quarter and year-end 2025 earnings results on Tuesday, March 31, 2026, after the market closes. PVH will sponsor a conference call on Wednesday, April 1, 2026, beginning at 9:00 A.M. Eastern Time, hosted by Stefan Larsson, Chief Executive Officer, and Melissa Stone, Interim Chief Financial Officer and Executive Vice President, Global Financial Planning & Analysis, to discuss the results. The call will be broadcast live over the Internet. A link will be available on the Company's website, www.pvh.com, under the Investors section. For those who are unable to listen to the live broadcast, the webcast replay will remain avai

    3/16/26 9:00:00 AM ET
    $PVH
    Garments and Clothing
    Industrials

    CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update

    - Announced Positive Data from Phase 1 Dose Expansion Study of varsetatug masetecan ("Varseta-M") EpCAM PROBODY® ADC in Patients with Advanced Colorectal Cancer (CRC) - - FDA interactions targeted for mid-year with goal to align on potential Varseta-M registrational trial design in late line CRC - - Varseta-M Phase 1 study evaluating combination with bevacizumab initiated; Phase 1b/2 chemotherapy combination study to be initiated by the end of 2026 - - Initial CX-801 PROBODY Interferon-alpha-2b Phase 1 combination data with KEYTRUDA® (pembrolizumab) in melanoma expected by the end of 2026 - - Company to host conference call today at 8 a.m. ET / 5 a.m. PT - SOUTH SAN FRANCISCO, Calif., M

    3/16/26 7:05:00 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AXDX
    $BDRX
    $BRDS
    $CDAK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Cidara Therapeutics Inc.

    SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)

    12/9/24 5:37:15 PM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by Accelerate Diagnostics Inc.

    SC 13D/A - Accelerate Diagnostics, Inc (0000727207) (Subject)

    12/5/24 5:13:13 PM ET
    $AXDX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by Cidara Therapeutics Inc.

    SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)

    12/4/24 4:15:14 PM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care